Asia

First made-in-Singapore cancer drug enters clinical testing

Thursday, July 23, 2015

A made-in-Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore’s biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide. The Agency for Science, Technology and Research (A*STAR) and Duke-National University of Singapore Graduate Medical School (Duke-NUS) have announced the start of a phase I clinical trial of novel cancer drug candidate, ETC-159.

[Read More]

Sun Pharma closes merger deal with Ranbaxy

Thursday, March 26, 2015

Sun Pharmaceutical Industries has begun the integration of Ranbaxy‘s business following the successful closure of its merger. The integration, planned by Sun Pharma since the announced merger in April 2014, will focus on supporting strong growth. According to Sun Pharma, the merger has fortified its position as the world’s fifth largest specialty generic pharmaceutical company and the top ranking Indian pharma company.

[Read More]

Eli Lilly inks deals with Innovent Biologics, Hanmi Pharmaceutical

Friday, March 20, 2015

Eli Lilly and Innovent Biologics, a biopharmaceutical company in China, have inked a biotech drug development collaboration to collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market.

[Read More]

Daiichi Sankyo opens collaborative research and grants program

Friday, March 20, 2015

Daiichi Sankyo, a global pharmaceutical company based in Japan, has announced its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2015. The company will select research partners for the project from researchers based in Japan. TaNeDS was launched in 2011 and has since received numerous research theme proposals from across Japan, with various projects currently ongoing.

[Read More]

Dako, Ono Pharmaceutical to collaborate on diagnostic test Opdivo

Wednesday, February 18, 2015

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

[Read More]